What does SynCore Biotechnology Co.,Ltd do?

SynCore Biotechnology Co.,Ltd (4192.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 4192.TWO's market cap?

SynCore Biotechnology Co.,Ltd (4192.TWO) has a market capitalization of approximately $701.5 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 4192.TWO pay a dividend?

No — SynCore Biotechnology Co.,Ltd (4192.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 4192.TWO profitable?

SynCore Biotechnology Co.,Ltd (4192.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

4192.TWO

SynCore Biotechnology Co.,Ltd

TWO·Biotechnology · Healthcare

NT$19.95NT$0.05−0.25%

Market capNT$701.54M·Aug 26 4:14 AM UTC

Price Chart

NT$19.95−NT$0.05 (−0.25%)today

−94.12%CAGR −43.27%

Select date range

FromTo

Aug 29, 2013Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

4192.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$26.24M

Net Income−NT$46.85M

Net Margin−178.5%

Operating Cash Flow−NT$32.41M

Capital ExpendituresNT$238.00K

Free Cash Flow−NT$32.65M

Return on Equity−21.4%

Return on Invested Capital−5.7%

Net CashNT$133.28M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 4192.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 4192.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4192.TWO and 80,000+ other tickers.

About SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical…

CEO: Chih-Wen Lee
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 40
Website: www.syncorebio.com

Peers

Peers Tab

6917.TWO

Andros Pharmaceuticals Co.,Ltd

Cap

NT$1.8B

6652.TWO

Eusol Biotech Co.,Ltd.

Cap

NT$268.5M

4732.TWO

NatureWise Biotech & Medicals Corporation

Cap

NT$857.3M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 4192.TWO

What does SynCore Biotechnology Co.,Ltd do?: SynCore Biotechnology Co.,Ltd (4192.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 4192.TWO's market cap?: SynCore Biotechnology Co.,Ltd (4192.TWO) has a market capitalization of approximately $701.5 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 4192.TWO pay a dividend?: No — SynCore Biotechnology Co.,Ltd (4192.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 4192.TWO profitable?: SynCore Biotechnology Co.,Ltd (4192.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.